View Future GrowthPharma Aids 過去の業績過去 基準チェック /56Pharma Aidsは、平均年間10%の収益成長を遂げていますが、 Packaging業界の収益は、年間 成長しています。収益は、平均年間5.6% 11.7%収益成長率で 成長しています。 Pharma Aidsの自己資本利益率は15.5%であり、純利益率は15.3%です。主要情報9.99%収益成長率9.99%EPS成長率Packaging 業界の成長2.63%収益成長率11.66%株主資本利益率15.53%ネット・マージン15.27%前回の決算情報31 Dec 2025最近の業績更新お知らせ • Apr 27Pharma Aids Limited to Report Q3, 2026 Results on Apr 29, 2026Pharma Aids Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2026 Results on Jan 29, 2026Pharma Aids Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 11+ 1 more updatePharma Aids Limited to Report Q1, 2026 Results on Nov 15, 2025Pharma Aids Limited announced that they will report Q1, 2026 results on Nov 15, 2025お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2025 Results on Nov 06, 2025Pharma Aids Limited announced that they will report fiscal year 2025 results on Nov 06, 2025お知らせ • Apr 28Pharma Aids Limited to Report Q3, 2025 Results on Apr 30, 2025Pharma Aids Limited announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 23Pharma Aids Limited to Report Q2, 2025 Results on Jan 30, 2025Pharma Aids Limited announced that they will report Q2, 2025 results on Jan 30, 2025すべての更新を表示Recent updatesお知らせ • Apr 27Pharma Aids Limited to Report Q3, 2026 Results on Apr 29, 2026Pharma Aids Limited announced that they will report Q3, 2026 results on Apr 29, 2026お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2026 Results on Jan 29, 2026Pharma Aids Limited announced that they will report Q2, 2026 results on Jan 29, 2026お知らせ • Nov 11+ 1 more updatePharma Aids Limited to Report Q1, 2026 Results on Nov 15, 2025Pharma Aids Limited announced that they will report Q1, 2026 results on Nov 15, 2025お知らせ • Nov 10Pharma Aids Limited, Annual General Meeting, Dec 24, 2025Pharma Aids Limited, Annual General Meeting, Dec 24, 2025, at 11:30 Central Asia Standard Time.お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2025 Results on Nov 06, 2025Pharma Aids Limited announced that they will report fiscal year 2025 results on Nov 06, 2025お知らせ • Apr 28Pharma Aids Limited to Report Q3, 2025 Results on Apr 30, 2025Pharma Aids Limited announced that they will report Q3, 2025 results on Apr 30, 2025お知らせ • Jan 23Pharma Aids Limited to Report Q2, 2025 Results on Jan 30, 2025Pharma Aids Limited announced that they will report Q2, 2025 results on Jan 30, 2025Reported Earnings • Nov 12Full year 2024 earnings released: EPS: ৳19.61 (vs ৳2.05 loss in FY 2023)Full year 2024 results: EPS: ৳19.61 (up from ৳2.05 loss in FY 2023). Revenue: ৳421.2m (up 37% from FY 2023). Net income: ৳61.2m (up ৳67.6m from FY 2023). Profit margin: 14% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.お知らせ • Nov 12Pharma Aids Limited to Report Q1, 2025 Results on Nov 13, 2024Pharma Aids Limited announced that they will report Q1, 2025 results on Nov 13, 2024New Risk • Nov 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (৳409m revenue, or US$3.4m). Market cap is less than US$100m (৳1.92b market cap, or US$16.0m).Declared Dividend • Nov 09Dividend of ৳2.50 announcedShareholders will receive a dividend of ৳2.50. Ex-date: 8th December 2024 Payment date: 23rd January 2025 Dividend yield will be 0.4%, which is lower than the industry average of 1.3%. Payout Ratios Payout ratio: 6%. Cash payout ratio: 11%.お知らせ • Nov 07Pharma Aids Limited, Annual General Meeting, Dec 24, 2024Pharma Aids Limited, Annual General Meeting, Dec 24, 2024, at 11:30 Central Asia Standard Time.Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳694, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 17x in the Packaging industry in Asia. Total returns to shareholders of 32% over the past three years.お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2024 Results on Nov 06, 2024Pharma Aids Limited announced that they will report fiscal year 2024 results on Nov 06, 2024Reported Earnings • Apr 26Third quarter 2024 earnings released: EPS: ৳7.46 (vs ৳1.21 loss in 3Q 2023)Third quarter 2024 results: EPS: ৳7.46 (up from ৳1.21 loss in 3Q 2023). Revenue: ৳116.7m (up 39% from 3Q 2023). Net income: ৳23.3m (up ৳27.0m from 3Q 2023). Profit margin: 20% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.お知らせ • Apr 21Pharma Aids Limited to Report Q3, 2024 Results on Apr 24, 2024Pharma Aids Limited announced that they will report Q3, 2024 results on Apr 24, 2024Reported Earnings • Jan 31Second quarter 2024 earnings released: EPS: ৳7.21 (vs ৳0.76 loss in 2Q 2023)Second quarter 2024 results: EPS: ৳7.21 (up from ৳0.76 loss in 2Q 2023). Revenue: ৳120.8m (up 63% from 2Q 2023). Net income: ৳22.5m (up ৳24.9m from 2Q 2023). Profit margin: 19% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2024 Results on Jan 30, 2024Pharma Aids Limited announced that they will report Q2, 2024 results on Jan 30, 2024Reported Earnings • Nov 14Full year 2023 earnings released: ৳2.05 loss per share (vs ৳11.14 profit in FY 2022)Full year 2023 results: ৳2.05 loss per share (down from ৳11.14 profit in FY 2022). Revenue: ৳308.5m (down 4.5% from FY 2022). Net loss: ৳6.38m (down 118% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.お知らせ • Nov 09Pharma Aids Limited Recommends Cash Dividend for the Year Ended June 30, 2023Pharma Aids Limited Board of Directors has recommended 10% cash dividend for the year ended June 30, 2023. Date of AGM is December 28, 2023, Record date is December 07, 2023.お知らせ • Nov 02Pharma Aids Limited to Report Fiscal Year 2023 Results on Nov 07, 2023Pharma Aids Limited announced that they will report fiscal year 2023 results on Nov 07, 2023Reported Earnings • May 02Third quarter 2023 earnings released: ৳1.21 loss per share (vs ৳4.63 profit in 3Q 2022)Third quarter 2023 results: ৳1.21 loss per share (down from ৳4.63 profit in 3Q 2022). Revenue: ৳83.8m (down 2.0% from 3Q 2022). Net loss: ৳3.76m (down 126% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.Reported Earnings • Jan 24Second quarter 2023 earnings released: ৳0.76 loss per share (vs ৳5.53 profit in 2Q 2022)Second quarter 2023 results: ৳0.76 loss per share (down from ৳5.53 profit in 2Q 2022). Revenue: ৳74.2m (down 8.6% from 2Q 2022). Net loss: ৳2.36m (down 114% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.Upcoming Dividend • Dec 04Upcoming dividend of ৳5.00 per shareEligible shareholders must have bought the stock before 11 December 2022. Payment date: 26 January 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (1.9%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳933, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 39x in the Packaging industry in Bangladesh. Total returns to shareholders of 78% over the past three years.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Feb 02Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳5.53 (up from ৳4.03 in 2Q 2021). Revenue: ৳81.1m (up 20% from 2Q 2021). Net income: ৳17.3m (up 37% from 2Q 2021). Profit margin: 21% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improved over the past weekAfter last week's 26% share price gain to ৳791, the stock trades at a trailing P/E ratio of 45.9x. Average trailing P/E is 15x in the Packaging industry in Asia. Total returns to shareholders of 23% over the past three years.Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳561, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 14x in the Packaging industry in Asia. Total loss to shareholders of 3.4% over the past three years.Upcoming Dividend • Dec 01Upcoming dividend of ৳5.00 per shareEligible shareholders must have bought the stock before 08 December 2021. Payment date: 30 January 2022. Trailing yield: 1.0%. Lower than top quartile of Bangladeshi dividend payers (3.1%). Lower than average of industry peers (2.1%).Is New 90 Day High Low • Feb 15New 90-day low: ৳393The company is down 6.0% from its price of ৳418 on 17 November 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Packaging industry, which is flat over the same period.Is New 90 Day High Low • Dec 20New 90-day high: ৳472The company is up 1.0% from its price of ৳468 on 21 September 2020. The Bangladeshi market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is down 6.0% over the same period.お知らせ • Nov 11Pharma Aids Limited, Annual General Meeting, Dec 24, 2020Pharma Aids Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time.お知らせ • Nov 10Pharma Aids Limited to Report Q1, 2021 Results on Nov 12, 2020Pharma Aids Limited announced that they will report Q1, 2021 results on Nov 12, 2020お知らせ • Jul 06Pharma Aids Limited to Report Q3, 2020 Results on Jun 24, 2020Pharma Aids Limited announced that they will report Q3, 2020 results on Jun 24, 2020収支内訳Pharma Aids の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DSE:PHARMAID 収益、費用、利益 ( )BDT Millions日付収益収益G+A経費研究開発費31 Dec 254747249030 Sep 254536748030 Jun 254386447031 Mar 254175346031 Dec 244326244030 Sep 244316744030 Jun 244216144031 Mar 244095144031 Dec 233762442030 Sep 23329-138030 Jun 23308-637031 Mar 23302-1346031 Dec 22303546030 Sep 223102546030 Jun 223233547031 Mar 223256040031 Dec 213155839030 Sep 213015439030 Jun 212805038031 Mar 212724637031 Dec 202554735030 Sep 202625134030 Jun 202705234031 Mar 202595132031 Dec 192655032030 Sep 192554832030 Jun 192494830031 Mar 192525026031 Dec 182465126030 Sep 182485027030 Jun 182354726031 Mar 182274624031 Dec 172123924030 Sep 171933522030 Jun 171803021031 Mar 171762820031 Dec 161662619030 Sep 161612518030 Jun 161522317031 Mar 161392317031 Dec 151372216030 Sep 151382316030 Jun 1514725150質の高い収益: PHARMAIDは 高品質の収益 を持っています。利益率の向上: PHARMAIDの現在の純利益率 (15.3%)は、昨年(14.5%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: PHARMAIDの収益は過去 5 年間で年間10%増加しました。成長の加速: PHARMAIDの過去 1 年間の収益成長率 ( 16% ) は、5 年間の平均 ( 年間10%を上回っています。収益対業界: PHARMAIDの過去 1 年間の収益成長率 ( 16% ) はPackaging業界4.2%を上回りました。株主資本利益率高いROE: PHARMAIDの 自己資本利益率 ( 15.5% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/07 00:19終値2026/05/07 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pharma Aids Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 27Pharma Aids Limited to Report Q3, 2026 Results on Apr 29, 2026Pharma Aids Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2026 Results on Jan 29, 2026Pharma Aids Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 11+ 1 more updatePharma Aids Limited to Report Q1, 2026 Results on Nov 15, 2025Pharma Aids Limited announced that they will report Q1, 2026 results on Nov 15, 2025
お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2025 Results on Nov 06, 2025Pharma Aids Limited announced that they will report fiscal year 2025 results on Nov 06, 2025
お知らせ • Apr 28Pharma Aids Limited to Report Q3, 2025 Results on Apr 30, 2025Pharma Aids Limited announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 23Pharma Aids Limited to Report Q2, 2025 Results on Jan 30, 2025Pharma Aids Limited announced that they will report Q2, 2025 results on Jan 30, 2025
お知らせ • Apr 27Pharma Aids Limited to Report Q3, 2026 Results on Apr 29, 2026Pharma Aids Limited announced that they will report Q3, 2026 results on Apr 29, 2026
お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2026 Results on Jan 29, 2026Pharma Aids Limited announced that they will report Q2, 2026 results on Jan 29, 2026
お知らせ • Nov 11+ 1 more updatePharma Aids Limited to Report Q1, 2026 Results on Nov 15, 2025Pharma Aids Limited announced that they will report Q1, 2026 results on Nov 15, 2025
お知らせ • Nov 10Pharma Aids Limited, Annual General Meeting, Dec 24, 2025Pharma Aids Limited, Annual General Meeting, Dec 24, 2025, at 11:30 Central Asia Standard Time.
お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2025 Results on Nov 06, 2025Pharma Aids Limited announced that they will report fiscal year 2025 results on Nov 06, 2025
お知らせ • Apr 28Pharma Aids Limited to Report Q3, 2025 Results on Apr 30, 2025Pharma Aids Limited announced that they will report Q3, 2025 results on Apr 30, 2025
お知らせ • Jan 23Pharma Aids Limited to Report Q2, 2025 Results on Jan 30, 2025Pharma Aids Limited announced that they will report Q2, 2025 results on Jan 30, 2025
Reported Earnings • Nov 12Full year 2024 earnings released: EPS: ৳19.61 (vs ৳2.05 loss in FY 2023)Full year 2024 results: EPS: ৳19.61 (up from ৳2.05 loss in FY 2023). Revenue: ৳421.2m (up 37% from FY 2023). Net income: ৳61.2m (up ৳67.6m from FY 2023). Profit margin: 14% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings.
お知らせ • Nov 12Pharma Aids Limited to Report Q1, 2025 Results on Nov 13, 2024Pharma Aids Limited announced that they will report Q1, 2025 results on Nov 13, 2024
New Risk • Nov 10New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported March 2024 fiscal period end). Revenue is less than US$5m (৳409m revenue, or US$3.4m). Market cap is less than US$100m (৳1.92b market cap, or US$16.0m).
Declared Dividend • Nov 09Dividend of ৳2.50 announcedShareholders will receive a dividend of ৳2.50. Ex-date: 8th December 2024 Payment date: 23rd January 2025 Dividend yield will be 0.4%, which is lower than the industry average of 1.3%. Payout Ratios Payout ratio: 6%. Cash payout ratio: 11%.
お知らせ • Nov 07Pharma Aids Limited, Annual General Meeting, Dec 24, 2024Pharma Aids Limited, Annual General Meeting, Dec 24, 2024, at 11:30 Central Asia Standard Time.
Valuation Update With 7 Day Price Move • Nov 04Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ৳694, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 17x in the Packaging industry in Asia. Total returns to shareholders of 32% over the past three years.
お知らせ • Oct 31Pharma Aids Limited to Report Fiscal Year 2024 Results on Nov 06, 2024Pharma Aids Limited announced that they will report fiscal year 2024 results on Nov 06, 2024
Reported Earnings • Apr 26Third quarter 2024 earnings released: EPS: ৳7.46 (vs ৳1.21 loss in 3Q 2023)Third quarter 2024 results: EPS: ৳7.46 (up from ৳1.21 loss in 3Q 2023). Revenue: ৳116.7m (up 39% from 3Q 2023). Net income: ৳23.3m (up ৳27.0m from 3Q 2023). Profit margin: 20% (up from net loss in 3Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
お知らせ • Apr 21Pharma Aids Limited to Report Q3, 2024 Results on Apr 24, 2024Pharma Aids Limited announced that they will report Q3, 2024 results on Apr 24, 2024
Reported Earnings • Jan 31Second quarter 2024 earnings released: EPS: ৳7.21 (vs ৳0.76 loss in 2Q 2023)Second quarter 2024 results: EPS: ৳7.21 (up from ৳0.76 loss in 2Q 2023). Revenue: ৳120.8m (up 63% from 2Q 2023). Net income: ৳22.5m (up ৳24.9m from 2Q 2023). Profit margin: 19% (up from net loss in 2Q 2023). The move to profitability was driven by higher revenue. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 81 percentage points per year, which is a significant difference in performance.
お知らせ • Jan 26Pharma Aids Limited to Report Q2, 2024 Results on Jan 30, 2024Pharma Aids Limited announced that they will report Q2, 2024 results on Jan 30, 2024
Reported Earnings • Nov 14Full year 2023 earnings released: ৳2.05 loss per share (vs ৳11.14 profit in FY 2022)Full year 2023 results: ৳2.05 loss per share (down from ৳11.14 profit in FY 2022). Revenue: ৳308.5m (down 4.5% from FY 2022). Net loss: ৳6.38m (down 118% from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
お知らせ • Nov 09Pharma Aids Limited Recommends Cash Dividend for the Year Ended June 30, 2023Pharma Aids Limited Board of Directors has recommended 10% cash dividend for the year ended June 30, 2023. Date of AGM is December 28, 2023, Record date is December 07, 2023.
お知らせ • Nov 02Pharma Aids Limited to Report Fiscal Year 2023 Results on Nov 07, 2023Pharma Aids Limited announced that they will report fiscal year 2023 results on Nov 07, 2023
Reported Earnings • May 02Third quarter 2023 earnings released: ৳1.21 loss per share (vs ৳4.63 profit in 3Q 2022)Third quarter 2023 results: ৳1.21 loss per share (down from ৳4.63 profit in 3Q 2022). Revenue: ৳83.8m (down 2.0% from 3Q 2022). Net loss: ৳3.76m (down 126% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has increased by 29% per year, which means it is well ahead of earnings.
Reported Earnings • Jan 24Second quarter 2023 earnings released: ৳0.76 loss per share (vs ৳5.53 profit in 2Q 2022)Second quarter 2023 results: ৳0.76 loss per share (down from ৳5.53 profit in 2Q 2022). Revenue: ৳74.2m (down 8.6% from 2Q 2022). Net loss: ৳2.36m (down 114% from profit in 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 22% per year, which means it is well ahead of earnings.
Upcoming Dividend • Dec 04Upcoming dividend of ৳5.00 per shareEligible shareholders must have bought the stock before 11 December 2022. Payment date: 26 January 2023. Payout ratio is a comfortable 26% and this is well supported by cash flows. Trailing yield: 0.6%. Lower than top quartile of Bangladeshi dividend payers (3.8%). Lower than average of industry peers (1.9%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Valuation Update With 7 Day Price Move • Aug 25Investor sentiment improved over the past weekAfter last week's 17% share price gain to ৳933, the stock trades at a trailing P/E ratio of 48.5x. Average trailing P/E is 39x in the Packaging industry in Bangladesh. Total returns to shareholders of 78% over the past three years.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (4 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 02Second quarter 2022 earnings: Revenues and EPS in line with analyst expectationsSecond quarter 2022 results: EPS: ৳5.53 (up from ৳4.03 in 2Q 2021). Revenue: ৳81.1m (up 20% from 2Q 2021). Net income: ৳17.3m (up 37% from 2Q 2021). Profit margin: 21% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates.
Valuation Update With 7 Day Price Move • Jan 22Investor sentiment improved over the past weekAfter last week's 26% share price gain to ৳791, the stock trades at a trailing P/E ratio of 45.9x. Average trailing P/E is 15x in the Packaging industry in Asia. Total returns to shareholders of 23% over the past three years.
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to ৳561, the stock trades at a trailing P/E ratio of 32.5x. Average trailing P/E is 14x in the Packaging industry in Asia. Total loss to shareholders of 3.4% over the past three years.
Upcoming Dividend • Dec 01Upcoming dividend of ৳5.00 per shareEligible shareholders must have bought the stock before 08 December 2021. Payment date: 30 January 2022. Trailing yield: 1.0%. Lower than top quartile of Bangladeshi dividend payers (3.1%). Lower than average of industry peers (2.1%).
Is New 90 Day High Low • Feb 15New 90-day low: ৳393The company is down 6.0% from its price of ৳418 on 17 November 2020. The Bangladeshi market is up 14% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Packaging industry, which is flat over the same period.
Is New 90 Day High Low • Dec 20New 90-day high: ৳472The company is up 1.0% from its price of ৳468 on 21 September 2020. The Bangladeshi market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Packaging industry, which is down 6.0% over the same period.
お知らせ • Nov 11Pharma Aids Limited, Annual General Meeting, Dec 24, 2020Pharma Aids Limited, Annual General Meeting, Dec 24, 2020, at 11:30 Bangladesh Standard Time.
お知らせ • Nov 10Pharma Aids Limited to Report Q1, 2021 Results on Nov 12, 2020Pharma Aids Limited announced that they will report Q1, 2021 results on Nov 12, 2020
お知らせ • Jul 06Pharma Aids Limited to Report Q3, 2020 Results on Jun 24, 2020Pharma Aids Limited announced that they will report Q3, 2020 results on Jun 24, 2020